Log in

NASDAQ:FBIOFortress Biotech Stock Price, Forecast & News

$2.02
+0.12 (+6.32 %)
(As of 04/10/2020 03:57 AM ET)
Add
Compare
Today's Range
$1.88
Now: $2.02
$2.06
50-Day Range
$1.14
MA: $1.85
$2.75
52-Week Range
$1.04
Now: $2.02
$3.11
Volume504,800 shs
Average Volume516,243 shs
Market Capitalization$158.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Read More
Fortress Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.63 million
Book Value$1.02 per share

Profitability

Net Income$-39,960,000.00
Net Margins-109.09%

Miscellaneous

Employees68
Market Cap$158.49 million
Next Earnings Date5/8/2020 (Estimated)
OptionableOptionable

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.


Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

How has Fortress Biotech's stock been impacted by COVID-19 (Coronavirus)?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FBIO shares have increased by 25.5% and is now trading at $2.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fortress Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fortress Biotech.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Fortress Biotech.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) posted its earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.04. The biopharmaceutical company had revenue of $11.13 million for the quarter, compared to analyst estimates of $11.61 million. Fortress Biotech had a negative net margin of 109.09% and a negative return on equity of 81.02%. View Fortress Biotech's earnings history.

What price target have analysts set for FBIO?

5 brokers have issued 12 month price targets for Fortress Biotech's shares. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's stock price to reach $9.20 in the next year. This suggests a possible upside of 355.4% from the stock's current price. View analysts' price targets for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:
  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019)

Has Fortress Biotech been receiving favorable news coverage?

News articles about FBIO stock have trended very negative this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fortress Biotech earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutFortress Biotech.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a decrease in short interest in February. As of February 28th, there was short interest totaling 687,000 shares, a decrease of 15.6% from the February 13th total of 814,100 shares. Based on an average daily trading volume, of 467,200 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.4% of the shares of the company are short sold. View Fortress Biotech's Current Options Chain.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL) and Geron (GERN).

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)
  • Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65)

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a number of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.22%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View institutional ownership trends for Fortress Biotech.

Which major investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View insider buying and selling activity for Fortress Biotech.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $2.02.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $158.49 million and generates $36.63 million in revenue each year. The biopharmaceutical company earns $-39,960,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe. View additional information about Fortress Biotech.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel